GSK looks abroad for more scientists as U.K. shortage grows

GlaxoSmithKline says that a dire shortage of science graduates in the U.K. is forcing the company to recruit new researchers from outside the country. According to a senior Glaxo executive, a number of U.K. universities have scrapped their chemistry departments in recent years in a drive to cut costs. Graduates from France, Spain, Germany and India have been recruited to fill the gap in what is seen as an increasingly globalized job market for drug development.

- here's the report from

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.